Correlation Engine 2.0
Clear Search sequence regions


  • cytokines (1)
  • patients (1)
  • platelet (1)
  • Sizes of these terms reflect their relevance to your search.

    Coronary artery disease is the leading cause of death worldwide, and its main pathological substrate is represented by atherosclerosis. Inflammation is a major promoter of the atherosclerotic process and is involved in both the initiation and progression of atherosclerosis, as well as in the occurrence of fatal complications. Until the present moment, Colchicine Cardiovascular Outcomes Trial is the largest trial to demonstrate a major benefit of low-dose colchicine on major adverse cardiac events in patients with recent myocardial infarction (MI), but the mechanisms behind this relation are not completely known. The purpose of this review is to emphasize the possible pathways through which colchicine improves the clinical outcomes in the acute setting of acute coronary syndromes by referring to the results of the studies published in the past 5 years. Aside from its stated systemic anti-inflammatory effect, colchicine could be a valuable addition to the therapeutic approach of acute MI by reducing the infarct size, stabilizing the coronary plaque, as well as reducing platelet aggregation. Moreover, colchicine may improve endothelial function, reduce the transcoronary release of cytokines, and prevent a rise in inflammatory markers after percutaneous coronary intervention, thus diminishing the residual inflammatory risk.

    Citation

    Laura Tapoi, Laura Benchea, Dimitrie Siriopol, Mehmet Kanbay, Adrian Covic. Colchicine Use in Acute Coronary Syndromes: An Update. Angiology. 2021 Jul;72(6):503-510


    PMID: 33412929

    View Full Text